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Background: Integrin 64 is overexpressed in pancreatic cancer and enhances invasion.
Results: Integrin 64 coordinately up-regulates AREG, EREG, and MMP1 through DNA demethylation and NFAT5 that in
turn enhances HGF-mediated invasion.
Conclusion: Integrin 64 stimulates HGF-dependent invasion through autocrine EGFR signaling.
Significance: HGF-stimulated invasion is dependent on autocrine EGFR signaling, thus implicating why EGFR inhibitors are
effective in a complex tumor microenvironment.
Integrin 64 is up-regulated in pancreatic adenocarcinomas
where it contributes to carcinoma cell invasion by altering the
transcriptome. In this study, we found that integrin 64 up-
regulates several genes in the epidermal growth factor receptor
(EGFR) pathway, including amphiregulin (AREG), epiregulin
(EREG), and ectodomain cleavage protease MMP1, which is
mediated by promoter demethylation and NFAT5. The correla-
tion of these genes with integrin 64 was confirmed in The
Cancer Genome Atlas Pancreatic Cancer Database. Based on
previous observations that integrin 64 cooperates with c-Met
in pancreatic cancers, we examined the impact of EGFR signal-
ing on hepatocyte growth factor (HGF)-stimulated migration
and invasion. We found that AREG and EREG were required for
autocrine EGFR signaling, as knocking down either ligand
inhibited HGF-mediated migration and invasion. We further
determined that HGF induced secretion of AREG, which is de-
pendent on integrin-growth factor signaling pathways, includ-
ing MAPK, PI3K, and PKC. Moreover, matrix metalloprotei-
nase activity and integrin 64 signaling were required for
AREG secretion. Blocking EGFR signaling with EGFR-specific
antibodies or an EGFR tyrosine kinase inhibitor hindered HGF-
stimulated pancreatic carcinoma cell chemotaxis and invasive
growth in three-dimensional culture. Finally, we found that
EGFR was phosphorylated in response to HGF stimulation that
is dependent on EGFR kinase activity; however, c-Met phosphor-
ylation in response to HGF was unaffected by EGFR signaling.
Taken together, these data illustrate that integrin 64 stimu-
lates invasion by promoting autocrine EGFR signaling through
transcriptional up-regulation of key EGFR family members and
by facilitating HGF-stimulated EGFR ligand secretion. These
signaling events, in turn, promote pancreatic carcinoma migra-
tion and invasion.
Integrins are heterodimeric transmembrane receptors
responsible for detecting and integrating signals from the extra-
cellular environment that provide a link between the extracel-
lular matrix and cytoskeleton. Of the 24 mammalian integrin
receptors, integrin 64 is overexpressed in nearly all pancre-
atic carcinomas where it stimulates malignant progression by
promoting tumor cell migration, invasion, and cell survival (1,
2). In normal epithelial cells, integrin 64 contributes to stable
attachment of cells to the basement membrane through forma-
tion of hemidesmosomes (3). However, during wound healing
and in advanced carcinomas, integrin 64 is phosphorylated,
and hemidesmosomes are subsequently disassembled. Upon
disassembly, integrin 64 is redistributed to the actin cyto-
skeleton where it cooperates with growth factor receptor sig-
naling to enhance cell migration and invasion (4, 5). Integrin
64 facilitates cell motility by promoting lamellipodia and
filopodia formation (6) as well as activating key pathways down-
stream of growth factor receptors such as PI3K, MAPK, Src
family kinases, and Rho family small GTPases (7, 8).
We have found that signaling through the integrin 64 dra-
matically alters the transcriptome, leading to the up-regulation
of key pro-invasion and metastatic genes such as autotaxin/
ENPP2 (9), S100A4 (10), and TIAM1 (11). In this study, we find
that in pancreatic carcinoma cells the integrin 64 stimulates
the expression of AREG2 and EREG, which are ligands for
EGFR.
EGFR and associated EGF-like ligands are dysregulated in
many cancers, including pancreatic, head and neck, breast,
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colorectal, lung, prostate, kidney, ovarian, brain, and bladder
(12). Signaling through the EGFR pathway mediates multiple
processes involved in tumor progression, including angiogene-
sis, invasion, migration, proliferation, and evasion of apoptosis
(13). Consequently, particular attention has been given to the
role of the EGFR pathway in the development of malignant
phenotypes, resulting in this pathway being targeted by a sub-
stantial array of chemotherapeutics.
There are seven ligands known to bind and signal through
EGFR as follows: EGF; transforming growth factor-; betacel-
lulin; heparin-binding EGF-like growth factor; epigen; AREG;
and EREG. Typically after ligand binding, activated EGFR com-
plexes are endocytosed, which leads to recruitment of the ubiq-
uitin ligase c-Cbl. Recruitment of c-Cbl promotes ubiquitina-
tion, lysosomal targeting, and degradation of EGFR (14).
However, AREG and EREG are unique in their downstream
signaling following ligand-receptor binding. Binding of AREG
or EREG to EGFR results in a transient recruitment of c-Cbl to
EGFR and a reduced level of ubiquitination. This property per-
mits EGFR recycling back to the plasma membrane where it
may continue signaling (15, 16). As a result, AREG and EREG
have been strongly implicated in tumor progression.
EGFR ligands are integral membrane proteins that typically
function in a paracrine and autocrine manner (17). For AREG,
this occurs when ADAM-17/TACE (18) or MMP1 (19) cleaves
the membrane precursor pro-AREG, releasing it into the extra-
cellular environment. This release creates feedback loops in
primary and metastatic sites to promote tumor progression.
AREG may also enter the bloodstream and travel to distant
organs, acting as an endocrine signal (20), and thus potentially
creating a favorable microenvironment (21). This property
allows tumors to maintain a high rate of proliferation with a
reduced requirement for exogenously supplied growth factors
(13). Notably, AREG has been demonstrated to stimulate pro-
liferation of pancreatic ductal cells and associate with an
increased frequency of lymph node involvement in pancreatic
cancer patients (22). Finally, AREG can induce EGF-indepen-
dent cell growth by acting as a self-sufficient growth signal in
serum-free conditions (23, 24). Likewise, EREG expression is
up-regulated in pancreatic cancer and contributes to cell
growth by binding to EGFR through paracrine and autocrine
loops (25). Similar to AREG, EREG is also cleaved at the cell
membrane by Adam-17/TACE (18). Once released, EREG can
stimulate the majority of the ErbB heterodimer receptor com-
binations (26). Although the affinity of EREG to EGFR is lower
compared with other EGFR ligands, its signaling potency is
higher, thus making EREG a more effective signaling ligand
(26).
In this study, we sought to understand how changes in the
transcriptome mediated by integrin 64 signaling affect pan-
creatic tumor cell invasion. Because the 4 integrin subunit
dimerizes exclusively with the 6 integrin subunit, we can study
cellular regulation from the integrin 64 by modulating integ-
rin 4 expression (11). We find that integrin 64 stimulates
the expression of AREG and EREG as well as the ectodomain
cleavage enzyme MMP1. We further provide evidence that
HGF stimulates the secretion of AREG, which is dependent on
integrin signaling pathways. This autocrine secretion in turn
promotes HGF-stimulated migration and three-dimensional
invasive growth of pancreatic carcinoma cells.
Experimental Procedures
Cell Lines and Cell Culturing—For this study, we used
AsPC1, Suit-2, and Panc-1 clones with either high or low
expression of the integrin 64, as described previously (11,
27). AsPC1, Suit-2, and Panc-1/3D7 cells were used as high
expressers of integrin 64. Panc-1/1G4 and Panc-1/2G6 cells
were used as low expressers of integrin 64. Panc-1/4cyt
clones lack the cytoplasmic domain of integrin 4 and were
used as a dominant negative for integrin 64. Suit-2 cells
(obtained from Dr. Takeshi Iwamura, Miyazaki Medical Col-
lege, Miyazaki, Japan) (28) and AsPC1 cells (obtained from
American Type Culture Collection, ATCC) were maintained in
RPMI 1640 medium. Clones generated from Panc-1 cells (from
ATCC) were grown in Dulbecco’s modified Eagle’s medium
(high glucose). All media were supplemented with 10% fetal
bovine serum (Sigma), 1% penicillin, 1% streptomycin, and 1%
L-glutamine (Gibco).
RNA Extraction and Real Time PCR—Cells were harvested
using TRIzol reagent (Invitrogen) to extract total RNA accord-
ing to the manufacturer’s protocol. RNA purity was determined
using the OD 260:280 ratio. cDNA was synthesized from 1 g of
RNA using the high capacity cDNA reverse transcription kit
(Applied Biosystems, Foster City, CA). Expression levels of
AREG, EREG, and MMP1 were assessed by real time quantita-
tive PCR (QPCR) using available probes, reagents, and a
StepOnePlus real time PCR system from Applied Biosystems.
Triplicate CT values were analyzed in Microsoft Excel using the
comparative CT (CT) method as described by the manufac-
turer (Applied Biosystems). The amount of target gene
expressed (2CT) was determined by normalizing to the
endogenous reference (18S or -actin) and relative to one of
the experimental samples. Data are representative of at least
three separate determinations.
For experiments using 5-aza-2-deoxycytidine (DAC), Panc-
1/2G6 (4 low), or Panc-1/4Cyt, cells were treated with 5 M
DAC (Sigma; dissolved in DMSO) or DMSO control for 5 days
in which fresh drug and medium were added every 24 h. After
treatment, cells were harvested and mRNA levels of AREG and
EREG measured by QPCR as described above.
Public Database Analysis—Correlations between gene expres-
sion (ITGB4, AREG, EREG, and MMP1) were analyzed by lin-
ear regression using the pancreatic adenocarcinoma dataset
(n  183) generated by the TCGA Research Network (cancer-
genome.nih.gov). The processed dataset was downloaded using
University of California Santa Cruz Cancer Browser (29). Sta-
tistical analyses were performed with GraphPad software (La
Jolla, CA).
Migration and Invasion Assays—Transwell chemotactic
migration assays were performed as described previously (11).
Briefly, for EGFR inhibition, cells were left untreated or treated
with EGFR tyrosine kinase inhibitor (TKI) (0.1 nM PD153035)
or EGFR neutralizing antibody (4 g/ml LA1) for 30 min. Tran-
swell chambers were coated with 15 g/ml laminin-1 for migra-
tion assays or with 10 g of Matrigel for invasion assays (Bio-
sciences). For all assays, the bottom chambers of Transwell
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(6.5-mm diameter, 8-m pore size; Corning) were coated with
15 g/ml laminin-1. Cells (5  104) were placed into the top
Transwell chamber and allowed to migrate for 4 h or to invade
for 6 h, in the presence of EGFR TKI or neutralizing antibody,
toward serum-free medium containing 50 ng/ml HGF  250
g/ml BSA or BSA alone as a control. Cells that did not migrate
or invade were removed from the top chamber using a cotton
swab. Cells attached to the bottom of the chamber were fixed
with 100% methanol, stained using 3% crystal violet in 2% eth-
anol, and counted visually using an inverted microscope.
Results are reported as the mean number of cells migrated per
mm2 from triplicate determinations. Data reported are repre-
sentative of at least three separate experiments.
Three-dimensional Culture—For three-dimensional culture
of pancreatic carcinoma cells, cells (5  103) in 200 l of low
serum media (5% FBS in high glucose DMEM) and 2% Matrigel
were seeded onto solidified growth factor reduced Matrigel (BD
Biosciences; 100 l per well of 8-well chamber slide). EGFR TKI
and EGFR neutralization antibody were added the next day.
Cells were fed with media containing 5% FBS and 2% Matrigel
every 2 days in the presence of EGFR TKI and EGFR antibody,
as indicated. Three-dimensional cultures were maintained for
10 –14 days before imaging. Phase contrast images of randomly
chosen fields were taken with a Nikon Ti-E inverted micro-
scope using Nikon Elements software. Images were cropped in
Adobe Photoshop and assembled in Adobe Illustrator CS5.
Gene Knockdown by RNAi—For siRNA treatment, cells from
70% confluent cultures were trypsinized, rinsed three times,
and resuspended in serum-free DMEM. Cells (3  106) were
electroporated without or with 200 nM non-targeting siRNA
(Dharmacon, Inc.) or 200 nM siRNA specific for NFAT5
(nuclear factor of activated T-cells 5) as described previously (9)
and replated under normal culturing conditions. Cells were col-
lected after 72 h and assessed for AREG and EREG expression
by QPCR as described above.
For stable knockdown of AREG and EREG, lentivirus was
produced by combining MISSION constructs for packaging
(psPAX2), envelope (pDM2G) vectors, and shRNA for AREG
or EREG or a non-targeting vector (pLKO.1) at a 4:2:1 ratio (all
vectors obtained from Sigma). Polyethyleneimine (Poly-
sciences) was combined with the DNA mixture at a 3:1 DNA to
polyethyleneimine ratio and added to 70% confluent HEK
293LTV cells that had been passaged 24 h prior. Conditioned
media were collected 24 and 48 h post-transfection and centri-
fuged at 5,000  g for 10 min, and viral supernatant was col-
lected. Panc-1/3D7 cells were passaged to 70% confluence in
10-cm dishes, and 4 ml of viral supernatant was added in com-
bination with 8 g/ml hexadimethrine bromide (Polybrene,
Sigma). Cells were placed under puromycin selection (2 g/ml)
for 3 days, and gene expression was measured by QPCR 24 h
following removal of puromycin. If knockdown efficiency was
at least 90%, migration and invasion assays were performed the
following day as described above.
AREG ELISA—Pancreatic carcinoma cells (1.5–2.0  105)
were plated in 6-well plates in complete culture medium. The
following day, cells were rinsed twice with PBS and then placed
in serum-free medium containing 250 g/ml BSA. For HGF
stimulation experiments, cells were rinsed after 4 h in serum-
free medium and then stimulated with HGF (10 or 50 ng/ml, as
noted). After 24 h, conditioned medium was harvested, cleared
by centrifugation, volume recorded, and AREG content ana-
lyzed by ELISA (human amphiregulin ELISA kit, catalog no.
ELH-AR-001, RayBiotech, Inc.) using recombinant human
AREG as a standard. Cells were counted by hemocytometer at
the conclusion of each experiment to confirm equal cell num-
bers. Data from triplicate determinations are reported as pico-
grams of AREG/ml/105 cells with standard deviation of the
mean. For all experiments, data presented are representative of
at least three separate determinations.
For inhibitor studies, cells were pretreated for 30 min with
DMSO only, 50 M PD98059 or 20 M U0126 (MEK/MAPK),
15 M H-89 (PKA), 2.5 M GF109203X (PKC), 1 M PP2 (Src),
or 20 M LY294002 (PI3K) after the initial serum starvation
steps. Medium was then changed, and cells were stimulated
with 50 ng/ml HGF in the presence or absence of inhibitor for
24 h before assessing the conditioned medium for AREG as
described above. For DAC experiments, cells were treated with
5 M DAC or DMSO as a control for 5 days, rinsed with PBS,
and serum-starved for 4 h in serum-free medium plus 250
g/ml BSA, and then stimulated with 50 ng/ml HGF in the
presence of DAC or DMSO as a control. The next day, condi-
tioned medium was analyzed for AREG expression levels as
described above.
Immunoprecipitation and Immunoblot Analysis—Suit-2
cells were plated on laminin-1-coated plates for 3 h and then
treated with EGFR TKI (PD153035) for 30 min prior to 5 or 30
min of stimulation with 50 ng/ml HGF, as noted. Cells were
harvested in cold RIPA buffer containing 50 mM sodium fluo-
ride, 10 mM sodium pyrophosphate, and 1 mM sodium
orthovanadate plus protease inhibitors. EGFR or c-Met was
immunoprecipitated from cell lysates using EGFR Erbitux
(Lilly, cetuximab) or c-Met-specific (Santa Cruz Biotechnology,
sc-161) antibodies, respectively, coupled to protein A/G-aga-
rose beads (Pierce). Beads were washed four times, and then
immunoprecipitates were separated by 6% SDS-PAGE, trans-
ferred, and immunoblotted for phosphotyrosine (PY20), EGFR
(Santa Cruz Biotechnology, sc-03), or c-Met (Santa Cruz Bio-
technology, sc-161), as indicated. Alternatively, cell lysates (80
g) from control or HGF-treated cells were separated by 8%
SDS-PAGE and immunoblotted with antibodies against
p-EGFR for site p-Y845 (catalog no. 2231S), p-Y1045 (catalog
no. 2237s), p-Y1068 (catalog no. 2234S), or p-Y1173 (catalog
no. 4407S) (from Cell Signaling) using total EGFR (catalog no.
sc-03, Santa Cruz Biotechnology) and/or actin (Sigma) as load-
ing controls. Data are representative of three separate
experiments.
Results
We (1) and others (2, 30, 31) have shown that integrin 64
is up-regulated in 92–100% of pancreatic adenocarcinomas.
Furthermore, this integrin can promote pancreatic carcinoma
invasiveness (11), in part through transcriptional regulation
(10, 11). Transcriptional profiling of integrin 64-responsive
genes (characterized in Ref. 11) revealed that integrin 64 is
associated with the substantial up-regulation of genes within
the EGFR pathway, including the EGFR ligands AREG and
Integrin 64 Stimulates Autocrine EGFR Signaling
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EREG and MMP1, a pro-tumorigenic protease that has been
previously shown to cleave the pro-form of AREG and EREG,
promoting autocrine release (19). These findings were vali-
dated by QPCR analysis. As shown in Fig. 1A, AREG and EREG
are induced over 1,000-fold and MMP1 over 300-fold in cells
with high integrin 64 expression compared with low
expressing clones and the parental Panc-1 population. The con-
tribution of integrin 64 was confirmed by stably reducing
integrin 64 using integrin 4-targeting shRNA in the high
integrin 4-expressing Panc-1 clone 3D7 (Fig. 1B) or by
expressing a dominant-negative form of integrin 4, which
lacks the cytoplasmic domain, into the Panc-1 cells (4cyt;
Fig. 1A). Furthermore, overexpression of a wild-type integrin
4 subunit into the low integrin 4-expressing clone (2G6)
stimulated expression of AREG, EREG, and MMP1 (Fig. 1C).
To confirm that these genes correlate with integrin 64
expression in human pancreatic tumors, we analyzed the
TCGA pancreatic ductal adenocarcinoma database, which con-
tains gene expression data as measured by RNAseq (see “Exper-
imental Procedures”). We find that each of these genes posi-
tively and significantly correlates with expression of the
integrin 4 subunit (ITGB4; Fig. 1D). These data demonstrate
that integrin 64 controls expression of AREG, EREG, and
MMP1 in pancreatic carcinoma cells.
Based on these correlations between the integrin 4 and
members of the EGFR family, we sought to explain mechanis-
tically how integrin 64 regulates their gene expression. It has
previously been established that integrin 4 can signal down-
stream to transcription factors, including NFAT1 and NFAT5,
to promote tumor cell invasion (10, 32). Considering that
FIGURE 1. Integrin 64 controls the mRNA expression of AREG, EREG, and MMP1. A–C, RNA was isolated from various Panc-1 clones, including Panc-1
parental cells, Panc-1 clones with low (1G4, 2G6) or high (3D7) expression of integrin 64, or a clone expressing a dominant-negative 4 that lacks the
cytoplasmic domain (4cyt) (A); from Panc-3D7 cells expressing a non-targeting shRNA construct (3D7) or cells in which 4 integrin was stably knocked down
with a specific shRNA (3D7-4 shRNA) (B); and from two Panc-2G6 clones overexpressing wild-type 4 (wt 4, C). RNA was assessed by QPCR (A–C) for expression
of AREG (top panels), EREG (middle panels), or MMP1 (bottom panels). Values were normalized to 18S and reported relative to Panc-2G6 using the 2CT
method, as described under the “Experimental Procedures.” Experiments are depicted as the mean relative mRNA expression  standard deviation of triplicate
determinations. D, these findings were validated in an external dataset (TCGA), where by linear regression the gene expression levels of the integrin 4 subunit
(ITGB4) were found to positively correlate with expression of AREG, EREG, and MMP1 in patient-derived pancreatic adenocarcinomas with p 	 0.0001.
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nuclear factor of activated T-cell consensus sites are found
within the AREG and EREG sequences, we hypothesized that
these genes could be targets for the nuclear factor of activated
T-cells. To determine whether AREG and EREG are regulated
by NFAT5 downstream of integrin 64 signaling, we used
siRNA to target NFAT5. We find that both AREG and EREG
expression are substantially decreased with NFAT5 knocked
down in integrin 4 low cells (2G6; Fig. 2A) and even more
robustly when integrin 4 is high (3D7; Fig. 2B). Knockdown of
NFAT5 by siRNA was confirmed by QPCR (Fig. 2, C and D).
These data indicate that the NFAT5 transcription factor is
required for expression of AREG and EREG in response to sig-
naling from the integrin 64.
Another mechanism by which the integrin 64 may regu-
lategeneexpressionofAREGandEREGisthroughDNAdemeth-
ylation. We previously found that integrin 64 controls the
DNA demethylation of select promoters in breast cancer,
including metastasis-associated protein S100A4 (10). To deter-
mine whether AREG and EREG were similarly controlled by
DNA demethylation, Panc-2G6 (4 low) and Panc-4cyt cells
were treated with the DNA methyltransferase inhibitor, DAC,
and assessed for expression by QPCR. We find that AREG,
EREG, and MMP1 expression are dramatically up-regulated
with DNA methyltransferase inhibition in Panc-2G6 cells (Fig.
2, E and G) and moderately up-regulated in Panc-3D7 cells (Fig.
2, F and H), indicating that gene expression is regulated by DNA
methylation, in response to signaling from the integrin 64.
Integrin 64 promotes invasion by cooperating with
growth factor receptors such as c-Met (4). Notably, c-Met and
its associated ligand, HGF, are important players in pancreatic
cancer (33). Therefore, we examined the individual contribu-
tions of AREG and EREG to HGF-mediated pancreatic cancer
cell migration and invasion. Although it is well established that
AREG and EREG contribute to cancer cell metastasis (25, 34),
how autocrine EGFR secretion contributes to directed cell
motility is less well defined. Therefore, we reduced AREG and
EREG expression in cells with high integrin 64 (3D7) using
target-specific shRNA, and we performed HGF-stimulated
chemotaxis and chemoinvasion. Cells were assessed for AREG
and EREG expression by QPCR (Fig. 3, E and F) the day prior to
chemotaxis and chemoinvasion assays. Inclusion in chemotaxis
and chemoinvasion required a minimum of 90% knockdown of
AREG or EREG. As shown in Fig. 3, AREG or EREG knockdown
results in decreased migration (Fig. 3, A and B) and invasion
(Fig. 3, C and D) of Panc-3D7 cells. Notably, effective knock-
down of one ligand resulted in decreased expression of the
other ligand by about 50%. These data indicate that both AREG
and EREG are required for HGF-mediated migration and inva-
sion of pancreatic cancer cells.
The need for EGFR signaling during HGF-stimulated che-
motaxis suggests that EGFR ligands may be released in
response to HGF signaling in cooperation with the integrin
64. To test this hypothesis, we utilized a human AREG
ELISA to assess AREG release from pancreatic cancer cells. For
these experiments, we first analyzed AREG secretion under
normal culturing conditions. As shown in Fig. 4A, we find that
AREG is secreted by cells expressing high integrin 64
(AsPC1, Suit-2, and 3D7) but not in integrin 4-low cells (2G6).
To determine whether HGF stimulates AREG release, cells
were serum-starved for 4 h and then treated with HGF over-
night. Conditioned medium was collected and tested for AREG
levels by ELISA (Fig. 4B). These data show that HGF stimulated
2– 4-fold greater AREG secretion versus controls in all three
cell lines tested. Considering that DAC can induce AREG and
EREG expression (Fig. 2C), we treated Panc-1 clones 2G6 and
4cyt with 5 M DAC for 5 days to induce expression of AREG
and test the impact of integrin 64 on the process of AREG
secretion. After treatment, cells were assessed for HGF-stimu-
lated AREG secretion by ELISA and compared with the Panc-
FIGURE 2. Integrin 64 regulates gene expression of AREG and EREG via
NFAT5 and DNA demethylation. Panc-1 clones 2G6 and 3D7 were electro-
porated with siRNA specific for NFAT5 or non-targeting (NT) control. After
72 h in culture, RNA was harvested from treated cells and assessed for AREG
and EREG expression (A and B) and for knockdown efficiency of NFAT5 (C and
D) by QPCR. To examine DNA methylation, Panc-1 clones 2G6 and 3D7 were
incubated for 5 days with or without 5 M DAC in fresh medium daily, as
noted. Cells were harvested, and gene expression levels of AREG, EREG, and
MMP1 were measured by QPCR, as noted (E–H). Experiments depicted here
are representative of at least three separate experiments. Data represent the
mean  S.D.
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3D7 cells. As shown in Fig. 4C, DAC induced AREG expression
to a level approximately one-quarter that of untreated Panc-
3D7 cells. With AREG secretion, however, the level of AREG in
the medium from unstimulated and HGF-stimulated cells dif-
fered by 20 – 60-fold higher in Panc-3D7 cells compared with
the Panc-4cyt and Panc-2G6 cells. This observation impli-
cates integrin 64 signaling in the secretion of AREG in addi-
tion to regulation by DNA demethylation. Taken together,
these data indicate that the integrin 64 can drive both
expression and subsequent release of AREG and that this
release is amplified by cross-talk with the c-Met receptor.
To resolve which pathways mediate HGF-stimulated AREG
release, specific inhibitors of growth factor signaling pathways
enhanced by integrins, including MAPK, PKA, Src, and PI3K (7,
35–39), and the classical PKC pathway, were tested for their
ability to block AREG secretion in response to HGF. As shown
in Fig. 5, inhibitors of the MEK-ERK, PKC and PI3K pathways
blocked HGF-mediated release of AREG in both Panc-3D7 and
FIGURE 3. AREG and EREG are both required for chemotactic migration
and invasion of pancreatic carcinoma cells. AREG or EREG expression levels
were reduced using lentiviral delivery of specific shRNAs. Upon stable selec-
tion with puromycin, cells were assessed for AREG (E) and EREG (F) expression
by QPCR. Populations that achieved a minimum of 90% reduction in expres-
sion of AREG or EREG specifically were assayed for migration or invasion the
following day. A–D, cells (5  104) were placed into the top well of laminin-1-
coated transwells for migration (A and C) or Matrigel-coated wells for invasion
(B and D) with either BSA containing DMEM (DMEM/BSA) alone or DMEM/BSA
with 50 ng/ml HGF in the bottom well, as described under “Experimental
Procedures.” Cells were allowed to migrate for 4 h or invade for 6 h prior to
harvest and quantification. Data depicted here are representative of at least
three different experiments and represent the mean  S.D. Statistical signif-
icance was calculated using a one-tailed t test in which *, p 	 0.05, and **, p 	
0.005. NT, non-targeting.
FIGURE 4. HGF stimulates secretion of AREG in cells with high integrin
64. A, AsPC1, Suit-2, Panc-2G6, and Panc-3D7 cells (1  105/well) were
plated in 6-well dishes containing complete growth medium overnight. The
next day, cells were washed with PBS, and culture medium was changed.
After 24 h, the conditioned medium was assayed for AREG by ELISA (RayBio-
tech) and reported as picograms of AREG/ml. B, cells (1  105/well) were
plated into 6-well dishes under normal culturing conditions. The following
day, cells were serum-starved for 4 h before medium was changed, and HGF
(0, 10, or 50 ng/ml, as noted) in serum-free medium was added. After 24 h,
culture medium for each condition was assessed for AREG content by ELISA,
and cells were counted to confirm equal cell numbers. C, cells were incubated
for 5 days with or without 5 M DAC in fresh medium daily. Cells were then
replated at 1.5  105 cells into 35- mm dishes on the 4th day. The following
day, cells were treated with either BSA or 50 ng/ml HGF as described in B and
then harvested the following day for conditioned medium assayed by AREG
ELISA. Data are reported as the mean picograms of AREG per ml of culture
medium per 1  105 cells  S.D. of triplicate determinations. Inset in C shows
gene expression analysis of AREG to confirm that DAC induced gene expres-
sion in the same experiment.
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Suit-2 cells. Notably, MEK inhibitors also impeded basal secre-
tion, thus suggesting that this pathway guides the basal secre-
tion of AREG as well as HGF-stimulated secretion.
The regulated release of EGFR ligands can be mediated by
metalloproteinases such as MMP1 (19). The MMPs that release
EGFR ligands can in turn be regulated by serine/threonine phos-
phorylation of their cytoplasmic domain by MAPK and other
kinase pathways (40). Given our observation that MMP1
expression is up-regulated by integrin 64, we tested the role
of MMP1 in HGF-mediated AREG secretion using the MMP
chemical inhibitor GM6001. As shown in Fig. 5C, the MMP
inhibitor strongly suppressed both basal and HGF-stimulated
AREG secretion, thus suggesting a critical role for MMP1 in
AREG secretion. Collectively, these data define an important
role for integrin 64 in the coordinated regulation of auto-
crine EGFR ligand expression and regulated release.
We determined that AREG and EREG are required for pan-
creatic cancer cell migration and invasion and that HGF
enhances integrin-mediated AREG secretion. Next, we sought
to determine whether activation of EGFR signaling facilitates
HGF-stimulated migration. For these experiments, we pre-
treated pancreatic carcinoma cells with either an EGFR
protein-tyrosine kinase inhibitor (PD153035) or an EGFR func-
tion-blocking antibody (LA1) prior to assessing HGF-stimu-
lated chemotaxis. As shown in Fig. 6, cells originating from a
primary tumor with high integrin 64 expression (Panc-3D7
and Suit-2; Fig. 6, A and C) were sensitive to EGFR inhibition.
Cells that had low integrin 64 (Panc-2G6, Fig. 6B) did not
chemotax well toward HGF, and this limited chemotactic
migration was not sensitive to EGFR signaling. However, inhi-
bition of EGFR signaling in AsPC1 cells (Fig. 6D), which are
derived from ascites (41), had no effect on cell migration toward
HGF.
Considering that autocrine secretion of EGFR ligands creates
a favorable microenvironment for proliferation and invasion,
we tested the effect of EGFR inhibitors on three-dimensional
invasive growth (42). Assessment of three-dimensional inva-
sion combines the effects of invasion and proliferation in a
more physiological three-dimensional environment. As shown
in Fig. 6E, EGFR inhibitors blocked invasive growth and limited
colonies to small acinar-like spherical masses in Panc-3D7 and
Suit-2 cells, as indicated. Notably, these inhibitors did not affect
AsPC1 cells in three-dimensional culture (Fig. 6E, bottom
panels).
To determine how c-Met-EGFR cross-talk impacts receptor
phosphorylation, we immunoprecipitated EGFR and c-Met
from Suit-2 cells that were left unstimulated or stimulated with
HGF in the presence or absence of an EGFR TKI. As shown in
Fig. 7A, we found that HGF stimulation led to an increase in
EGFR phosphorylation and that this phosphorylation was
blocked by the EGFR TKI; however, c-Met phosphorylation
was unaffected by EGFR signaling. We next examined the phos-
phorylation of individual tyrosines in EGFR in response to
HGF. We found that treatment with HGF stimulated phosphor-
ylation of EGFR at multiple sites. As shown in Fig. 7B, the phos-
phorylation site with the most dramatic increase in phosphor-
ylation upon HGF treatment was tyrosine 845, which is
phosphorylated by Src and leads to the activation of the kinase
domain of EGFR (43). Phosphorylation of the Grb2- (Tyr-1068)
and Shc (Tyr-1173)-docking sites were also enhanced by HGF
stimulation, whereas the Cbl-binding site (Tyr-1045) was min-
imally impacted (Fig. 7B).
Next, we compared the impact of HGF stimulation on EGFR
phosphorylation in various cells to determine how the AsPC1
cells might differ from the other pancreatic carcinoma cell
lines. We found that AsPC1 cells have markedly higher basal
EGFR phosphorylation level (Fig. 7C) compared with other
pancreatic cancer cell lines. Furthermore, HGF stimulation led
to a slightly lower level of phosphorylation of Tyr-1068 and
Tyr-1173 with HGF stimulation (Fig. 7C), which was a consis-
tent finding among experiments. Collectively, these data indi-
cate that HGF stimulates autocrine release of the EGFR ligands
FIGURE 5. HGF-stimulated release of AREG from cells requires MAPK,
PKC, and PI3K. Panc-3D7 (A) and Suit-2 (B) cells (2  105/well) were serum-
starved for 4 h as described in Fig. 4B. Cells were then treated with inhibitors
of MAPK/MEK (PD98059, U0126), PKA (H89), PKC (GF109203X (GFX)), Src (PP2),
and PI3K (LY294002 (LY)) for 15 min as described under “Experimental Proce-
dures.” Alternatively, Panc-3D7 cells (C) were treated with general metallo-
proteinase inhibitor GM6001 (GM) at the indicated concentration (20 or 50
M). Cells were then stimulated with HGF in the presence of the indicated
inhibitor for 24 h before conditioned medium was assessed for AREG content
by ELISA, and cells were counted by a hemocytometer. Data are reported as
picograms of AREG per ml of culture medium per 1  105 cells and are repre-
sentative of at least three different experiments. Data are reported as the
mean of triplicate determinations  S.D.
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AREG and EREG and that this signaling in turn activates EGFR,
which further propagates c-Met signaling. Furthermore, these
data suggest that the high basal level of EGFR phosphorylation
and insensitivity of this phosphorylation status to c-Met signal-
ing may underlie the resistance of AsPC1 cells to EGFR
inhibition.
Discussion
Integrin 64 is highly up-regulated in pancreatic cancer (1,
2) and potentiates an invasive phenotype in response to multi-
ple growth factor receptors, including EGFR, c-Met, FGF, Ron,
and lysophosphatidic acid receptors (4, 44 – 46). Our group (9)
and others (32, 47, 48) have demonstrated that integrin 64
can activate important tumor-promoting transcription factors
such as NFAT1, NFAT5, NFB and AP-1. These factors, along
with DNA demethylation of specific genes (10), alter the tran-
scriptome to facilitate an invasive phenotype. Here, we expand
on these observations and find that integrin 64 coordinates
the increased expression of multiple components of the EGFR
pathway, including a slight elevation in receptor expression
(data not shown), de novo expression of the EGFR ligands
AREG and EREG, and elevation of a key protease responsible
for cleavage of these EGFR ligands into soluble growth factors.
We find that both the transcription factor NFAT5 as well as
DNA demethylation are required for expression and that integ-
rin 64 is needed for the subsequent secretion of AREG and
EREG. Using the TCGA dataset on pancreatic ductal adenocar-
cinoma, we find that AREG, EREG, and MMP1 correlate
strongly with expression of the integrin 4 subunit, which is
indicative of integrin 64 expression. This coordinated regu-
lation of the EGFR ligands has been shown previously as a
mechanism for pathway dependence in pancreatic cancer (49).
Notably, we find that the combination of these genes permits
FIGURE 6. EGFR signaling is required for HGF-stimulated chemotaxis and
invasive growth in pancreatic carcinoma cells overexpressing integrin
64. A–D, Panc-1 clones 3D7 (A) or 2G6 (B) or Suit-2 (C) or AsPC1 (D) cells
were left untreated or treated with EGFR TKI (0.1 nM PD153035) or EGFR neu-
tralizing antibody (4 g/ml LA1) for 30 min. Cells (5  104) were placed into
the top of laminin1-coated transwells and allowed to migrate for 4 h toward
BSA or 50 ng/ml HGF in the presence of drug. Data depicted here are repre-
sentative of at least three different experiments and represent the mean 
S.D. Asterisks represent a p value of 	0.002 compared with controls (no
drug). Other bars are not significantly different from their controls. E, Panc-
3D7, Suit-2, or AsPC-1 cells (as noted) were grown in Matrigel under reduced
serum conditions for 10 days as described under “Experimental Procedures.”
EGFR TKI (0.1 nM PD153035) or EGFR antibody (4 g/ml LA1) were added
every 2 days at feeding. Note that both treatments limited growth of spheres
and inhibited invasion from the spheres in Panc-3D7 and Suit-2 cells but not
AsPC-1. Invasion of control cells is noted with arrowheads.
FIGURE 7. HGF stimulates EGFR phosphorylation, but EGFR signaling
does not affect HGF-dependent phosphorylation of c-Met. A, Suit-2 cells
were plated on laminin-1-coated plates for 3 h and then treated with EGFR TKI
(PD153035) for 30 min prior to 5 or 30 min of stimulation with 50 ng/ml HGF
where noted. EGFR or c-Met were immunoprecipitated from cell lysates and
immunoblotted for phosphotyrosine (PY20), EGFR, or c-Met as indicated. B,
Suit-2 cells were plated on laminin-1-coated dishes as in A and stimulated
with 5 ng/ml EGF or 50 ng/ml HGF (HGF50) or 100 ng/ml HGF (HGF100) for 5
min as indicated before harvesting immunoblot analysis. C, Panc-2G6, Panc-
3D7, AsPC-1, and Suit2 cells were seeded into 60-mm dishes, serum-starved
overnight, and then stimulated with 50 ng/ml HGF for 5 min. Cell lysates were
then immunoblotted with EGFR phosphotyrosine antibodies as noted (B and
C). Total EGFR and actin were used as controls.
Integrin 64 Stimulates Autocrine EGFR Signaling
NOVEMBER 6, 2015 • VOLUME 290 • NUMBER 45 JOURNAL OF BIOLOGICAL CHEMISTRY 27235
 by guest on D
ecem
ber 1, 2016
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
pancreatic cancer cells to secrete EGFR ligands in response to
HGF and, in turn, to promote the efficiency of HGF-mediated
invasion and migration.
We further find that both AREG and EREG are required for
HGF-mediated invasion and migration of pancreatic carci-
noma cells. Notably, the contributions of AREG and EREG as
pro-oncogenic factors in pancreatic cancer have previously
been established (22, 50). Signaling from AREG, specifically
autocrine secretion, has been implicated in chemoresistance,
evasion of apoptosis, self-sufficiency in growth signals, prolif-
eration, angiogenesis, invasion, and metastasis (20). In fact,
AREG secretion levels in pancreatic cancer patients are ele-
vated to the point that this ligand has been identified as a poten-
tial biomarker that is associated with a worse outcome (51). It
may be that high levels of AREG are needed because of its low
affinity for the receptor compared with other ligands. EREG, for
example, is found at much lower concentrations but has a
broader specificity for ErbB receptors and very high binding
affinity, thus resulting in more potent signaling (26).
The involvement of integrin 64 in the regulation and
secretion of growth factors that facilitate invasion appears to be
an unexpectedly common event. Previous work from Mercurio
and co-works (52) demonstrated that integrin 64 controls
the Hif1-mediated translation of VEGF, which then produces
an autocrine effect to promote invasion and survival of breast
carcinoma cells. Our laboratory has also previously shown that
integrin 64 regulates the expression of the autocrine motility
factor autotaxin (9) and S100A4/metastasin-1 (10), both of
which can promote the migration and invasion of breast cancer
cells. The ability of integrin 64 to promote the expression
and secretion of factors such as autotaxin, S100A4, VEGF,
AREG, and EREG suggests that autocrine secretion is a major
function of integrin 64-mediated migration and invasion.
Downstream of these secreted factors, integrin 64 is also well
known for cooperating with various growth factor receptors,
including EGFR, c-Met, and LPAR1 to amplify Rho family
GTPase family members Rac (11, 53) and Rho (8, 54). These
events in turn permit cell polarization and enhanced cell motil-
ity and invasion. Despite our understanding of these signaling
pathways, how the regulated autocrine secretion helps drive
migration and invasion is not well understood. According to
our findings, cells can migrate in the absence of productive
autocrine signaling (e.g. Panc-2G6), but this migration is not
efficient. Furthermore, integrin-mediated signaling cooperates
with HGF to stimulate AREG release (Fig. 5). Together, these
observations suggest that integrin signaling and EGFR ligand
secretion can amplify specific signals to promote pancreatic
cancer cell migration and invasion.
These results led us to a model (Fig. 8) where signaling from
the integrin 64 promotes enhanced transcription of MMP1,
AREG, EREG, and EGFR, which are subsequently expressed at
the cell surface. Activation of c-Met by HGF results in cooper-
ative signaling with the integrin 64 leading to activation of
MMP1. MMP1 cleaves AREG and EREG proproteins, releasing
them into the extracellular space, allowing binding to and acti-
vation of EGFR. This amplified signaling network results in
enhanced pancreatic cancer cell invasion and migration.
EGFR inhibitors have been quite effective in treating a variety
of cancers (55). Despite this success, resistance is often a signif-
icant problem. The mechanisms governing resistance to EGFR-
based treatments have been an active field of research. Perhaps
the more pertinent question is why do EGFR inhibitors work at
all given the prevalence and variety of growth factors present in
the tumor stroma that could promote proliferation and inva-
sion? The answer to this question may reside in the ability of
EGFR to potentiate signaling from other growth factors. Our
study demonstrates a surprising dependence of c-Met signaling
on EGFR for more efficient guidance of tumor cell migration
and invasion. Previous studies have highlighted the ability of
lysophosphatidic acid signaling to cause transactivation of
EGFR resulting in increased cancer cell invasion (56, 57).
Accordingly, the effectiveness of EGFR inhibitors may be medi-
ated, in part, by the dependence of other growth factor signaling
on EGFR. c-Met signaling is well recognized as a mechanism of
resistance for EGFR inhibitors (58). This is highlighted by the
effective use of the c-Met inhibitor crizotinib in the clinic to
treat EGFR inhibitor-resistant cancers such as non-small cell
lung cancer (NSCLC) (59). Furthermore, a 2011 study by Sieg-
fried and co-workers (62) found that EGFR signaling in NSCLC
led to the delayed Src-dependent activation of the c-Met recep-
tor in a manner that appears to be independent of HGF. They
further discovered that inhibition of both growth factors was
required for effective treatment of NSCLC growth in a xeno-
graft model. Other mechanisms of resistance to EGFR inhibi-
tors include the mutation, overexpression, or hyperactivation
of EGFR (60, 61). Notably, we see in our studies that AsPC1 cells
FIGURE 8. Cooperative signaling between EGFR, c-Met, and integrin
64 promotes pancreatic cancer cell migration and invasion. Integrin
64 signaling enhances transcription of EGFR ligands, AREG and EREG, as
well as MMP1 and EGFR (1). Translated proteins are brought to the cell surface
for activation (2). Upon HGF-mediated stimulation (3), c-Met and integrin sig-
naling cooperate to activate MMP1 (4) through the MAPK, PKC, and PI3K path-
ways (data not shown). MMP1 cleaves AREG and EREG proproteins (5), which
in turn are released and lead to autocrine activation of EGFR (6) and result in
enhanced cell migration and invasion (7).
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overexpress EGFR but also display dramatic hyperactivation of
EGFR under unstimulated conditions, which may contribute to
the inherent resistance of this cell line to EGFR inhibitors.
Therefore, we propose that the ability for EGFR to cooperate
with and potentiate signaling from other growth factors should
be duly noted as a potent method for facilitating tumor inva-
sion. Furthermore, by understanding these signaling events,
other mechanisms of EGFR resistance may be uncovered.
In summary, our study demonstrates that integrin 64
signaling coordinately regulates the expression of the EGFR
ligands AREG and EREG and the ectodomain cleavage protease
MMP1. Furthermore, this integrin facilitates the regulated
secretion of AREG in response to HGF stimulation, thus lead-
ing to cell polarization and enhanced migration and invasion. In
total, we define a new coordinated autocrine signaling loop
mediated by integrin 64 signaling as well as a novel depen-
dence of HGF-c-Met signaling on the autocrine EGFR signaling
pathway (Fig. 8). This observation may help to explain why
EGFR inhibitors can be therapeutically effective in a complex
tumor microenvironment composed of many different growth
factors.
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